GBA Presents: House of Gummy-!
- Thread starter stonedinvestor
- Start date
STONEY!!!!This " kid " has a boatload from three threads ago at $1.00
The TTWO 12/8 $155 calls will be on deep discount. Buy at $0.80 at the bell.
Well you know how those intra-day charts go on the high flyers everyone is playing. Ya gotta strike when the iron gets hot. Then get out.I supposed if I was patient I could have bought at $109
Goooooood Morning!
I have been working on a biotech idea.
Today I am ready to release it.- The name is Icosavax.//
I am not thrilled that is a vaccine stk. I feel there has been investor let down in the overall sector-- but this is not for Covid. It is for RSV which is important and a nice kicker it is a combo shot that also takes care of hMPV- which is right on the fringe kind of problem --they warn about and nobody really gets a shot for but younger folks probably should...
As all great investments go they start by accident-- This name is on my watch list and I don't really know why/
Last week Guggeheim gave a nice upgrade that drove the stk and that is probably the reason I started following.
Timing-
Operational Progress and Future Outlook
Adam Simpson, Chief Executive Officer of Icosavax, expressed satisfaction with the company's clinical data updates and pipeline progress. The company's lead program, IVX-A12, a combination vaccine candidate for RSV and hMPV, is on track to report topline interim results by the end of 2023. The Phase 1 six-month durability data for IVX-A12 is expected in the first quarter of 2024. Additionally, Icosavax has completed candidate selection for its SARS-CoV-2 and influenza programs, demonstrating the company's antigen design capabilities.
We are pleased with our clinical data updates and continued pipeline progress this year. IVX-A12, our potential first-in-class combination vaccine candidate for RSV and hMPV, could address a significant unmet need and represent a large market opportunity for the company," said Adam Simpson, Chief Executive Officer of Icosavax.
It seems to me we have some news that should come at the end of this year and slightly into next which makes it a prime hold idea*
CASH-
Balance Sheet and Statements of Operations
The balance sheet shows a solid financial position, with total assets amounting to $251.3 million. The company's liabilities totaled $18.9 million, resulting in total stockholders' equity of $232.4 million. The condensed statements of operations reflect the company's focus on research and development, with significant investment in this area contributing to the net loss.
The anticipated data from the IVX-A12 Phase 2 study could be a pivotal moment for the company, potentially positioning Icosavax as a leader in the respiratory vaccine market.
THE CALL-
BUY->Icosavax, Inc. (ICVX) @$11 AREA
NasdaqGS - NasdaqGS Real Time Price.
11.12+0.62(+5.90%)
At close: December 4 04:00PM EST
11.09-0.03(-0.27%)
Pre-Market:08:00AM EST
I have been working on a biotech idea.
Today I am ready to release it.- The name is Icosavax.//
I am not thrilled that is a vaccine stk. I feel there has been investor let down in the overall sector-- but this is not for Covid. It is for RSV which is important and a nice kicker it is a combo shot that also takes care of hMPV- which is right on the fringe kind of problem --they warn about and nobody really gets a shot for but younger folks probably should...
As all great investments go they start by accident-- This name is on my watch list and I don't really know why/
Last week Guggeheim gave a nice upgrade that drove the stk and that is probably the reason I started following.
Timing-
Operational Progress and Future Outlook
Adam Simpson, Chief Executive Officer of Icosavax, expressed satisfaction with the company's clinical data updates and pipeline progress. The company's lead program, IVX-A12, a combination vaccine candidate for RSV and hMPV, is on track to report topline interim results by the end of 2023. The Phase 1 six-month durability data for IVX-A12 is expected in the first quarter of 2024. Additionally, Icosavax has completed candidate selection for its SARS-CoV-2 and influenza programs, demonstrating the company's antigen design capabilities.
We are pleased with our clinical data updates and continued pipeline progress this year. IVX-A12, our potential first-in-class combination vaccine candidate for RSV and hMPV, could address a significant unmet need and represent a large market opportunity for the company," said Adam Simpson, Chief Executive Officer of Icosavax.
It seems to me we have some news that should come at the end of this year and slightly into next which makes it a prime hold idea*
CASH-
Balance Sheet and Statements of Operations
The balance sheet shows a solid financial position, with total assets amounting to $251.3 million. The company's liabilities totaled $18.9 million, resulting in total stockholders' equity of $232.4 million. The condensed statements of operations reflect the company's focus on research and development, with significant investment in this area contributing to the net loss.
The anticipated data from the IVX-A12 Phase 2 study could be a pivotal moment for the company, potentially positioning Icosavax as a leader in the respiratory vaccine market.
THE CALL-
BUY->Icosavax, Inc. (ICVX) @$11 AREA
NasdaqGS - NasdaqGS Real Time Price.
11.12+0.62(+5.90%)
At close: December 4 04:00PM EST
11.09-0.03(-0.27%)
Pre-Market:08:00AM EST
HF'S & INSTITUTIONS LIKE BIOTECHS BUT THEY REALLY LIKE THIS ONE-
Institutional Trading of Icosavax
A number of hedge funds have recently made changes to their positions in ICVX. TCG Crossover Management LLC acquired a new stake in shares of Icosavax in the second quarter valued at approximately $36,778,000. Price T Rowe Associates Inc. MD lifted its position in shares of Icosavax by 82.1% in the second quarter. Price T Rowe Associates Inc. MD now owns 3,342,470 shares of the company’s stock valued at $19,152,000 after buying an additional 1,506,613 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in Icosavax by 34.6% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,463,525 shares of the company’s stock worth $35,441,000 after purchasing an additional 1,148,465 shares during the last quarter. FMR LLC lifted its holdings in Icosavax by 22.9% during the 1st quarter. FMR LLC now owns 6,003,002 shares of the company’s stock worth $34,817,000 after purchasing an additional 1,117,631 shares during the last quarter. Finally, BlackRock Inc. lifted its holdings in Icosavax by 36.3% during the 2nd quarter. BlackRock Inc. now owns 1,786,140 shares of the company’s stock worth $17,736,000 after purchasing an additional 475,777 shares during the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.
Institutional Trading of Icosavax
A number of hedge funds have recently made changes to their positions in ICVX. TCG Crossover Management LLC acquired a new stake in shares of Icosavax in the second quarter valued at approximately $36,778,000. Price T Rowe Associates Inc. MD lifted its position in shares of Icosavax by 82.1% in the second quarter. Price T Rowe Associates Inc. MD now owns 3,342,470 shares of the company’s stock valued at $19,152,000 after buying an additional 1,506,613 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in Icosavax by 34.6% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,463,525 shares of the company’s stock worth $35,441,000 after purchasing an additional 1,148,465 shares during the last quarter. FMR LLC lifted its holdings in Icosavax by 22.9% during the 1st quarter. FMR LLC now owns 6,003,002 shares of the company’s stock worth $34,817,000 after purchasing an additional 1,117,631 shares during the last quarter. Finally, BlackRock Inc. lifted its holdings in Icosavax by 36.3% during the 2nd quarter. BlackRock Inc. now owns 1,786,140 shares of the company’s stock worth $17,736,000 after purchasing an additional 475,777 shares during the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.
HE DID IT AGAIN!!!!
$157
WILL WE HIT VAN'S $170 TARGET BY FRIDAY?
--->Ancient astronaut theorists say "yes".
ANOTHER IDEA: Been looking through these EVTOL plays ARCHR etc... and old school HON is a backdoor play here on this theme...
I'll have more on this shortly but strongly considering HON. (IRA type buy)
I'll have more on this shortly but strongly considering HON. (IRA type buy)
There is a heck of a debate going on over this clip- did it really happen and so loud and at just the right time.. But The NY post has this up so it has to be true-